subscribeSubscribe
Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma

Blockbuster cancer drug Calquence hits primary endpoint in trial for first-line mantle cell lymphoma
PRESS RELEASE
03 May 2024
Share Share
CALQUENCE Combo Shows PFS Benefit In 1st-Line Mantle Cell Lymphoma

CALQUENCE Combo Shows PFS Benefit In 1st-Line Mantle Cell Lymphoma
BUSINESSWIRE
02 May 2024
Share Share
FDA Confirms Para IV Patent for Acalabrutinib Maleate (Calquence) Tablets

FDA Confirms Para IV Patent for Acalabrutinib Maleate (Calquence) Tablets

FDA
01 May 2024
Share Share
AstraZeneca beats revenue, profit estimates on resilient demand

AstraZeneca beats revenue, profit estimates on resilient demand
REUTERS
25 Apr 2024
Share Share
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib
BUSINESSWIRE
29 Feb 2024
Share Share
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration

Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration
PR NEWSWIRE
15 Oct 2023
Share Share
China NMPA approves AstraZeneca’s BTK inhibitor, Calquence

China NMPA approves AstraZeneca’s BTK inhibitor, Calquence
PHARMABIZ
04 Sep 2023
Share Share
AstraZeneca BTK inhibitor tablet approved in EU for leukaemia

AstraZeneca BTK inhibitor tablet approved in EU for leukaemia
EUROPEAN PHARMACEUTICAL REVIEW
23 Feb 2023
Share Share
Alembic`s Generic Acalabrutinib Receives Approval in the U.S.

Alembic`s Generic Acalabrutinib Receives Approval in the U.S.
FDA
18 Jan 2023
Share Share
Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication

Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
PHARMABIZ
24 Dec 2022
Share Share